BEconneCTD-ILD (BElimumab for conneCtive Tissue Disease ILD)] Phase 3, randomized, double-blind, placebocontrolled, parallel group study to evaluate the efficacy and safety of belimumab administered subcutaneously in adults with interstitial lung di